Trade Report: Today, Sentry Investment Management LLC invests in Regeneron Pharmaceuticals Inc. (REGN) Shares

Today, Sentry Investment Management LLC invests in Regeneron Pharmaceuticals Inc. (REGN) Shares

Sentry Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 3.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,083 shares of the biopharmaceutical company’s stock after buying an additional 189 shares during the period. Sentry Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $2,445,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in REGN. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the period. Advisory Services Network LLC increased its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 34 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Finally, NEXT Financial Group Inc increased its position in Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 115 shares during the period. Institutional investors own 68.45% of the company’s stock.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) opened at 402.41 on Friday. Regeneron Pharmaceuticals Inc. has a one year low of $325.35 and a one year high of $566.52. The company has a 50 day moving average of $381.56 and a 200-day moving average of $389.13. The stock has a market cap of $42.19 billion, a price-to-earnings ratio of 58.71 and a beta of 1.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The company earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the company earned $3.47 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

A number of research analysts have commented on the stock. RBC Capital Markets reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, August 6th. Leerink Swann set a $511.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 6th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 10th. JPMorgan Chase & Co. set a $477.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, October 30th. Finally, Piper Jaffray Cos. set a $447.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, October 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $468.87.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $450.00, for a total value of $956,250.00. Following the completion of the sale, the director now owns 15,125 shares of the company’s stock, valued at $6,806,250. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 2,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total value of $858,680.00. Following the completion of the sale, the director now directly owns 36,500 shares of the company’s stock, valued at approximately $15,670,910. The disclosure for this sale can be found here. 10.40% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Related posts

Leave a Comment